Myotonic Dystrophy Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Myotonic Dystrophy Therapeutics | DelveInsight

DelveInsight's Myotonic Dystrophy Pipeline Insight 2026 report provides comprehensive global coverage of available and pipeline Myotonic Dystrophy therapies across various stages of clinical and nonclinical development. More than 20 companies are working to advance 22+ pipeline drugs, with pharmaceutical and biotechnology companies developing novel therapeutic approaches aimed at addressing the underlying genetic mechanisms and multisystem manifestations associated with Myotonic Dystrophy.

Key takeaways from the Myotonic Dystrophy Clinical Trial Landscape Report

• DelveInsight's Myotonic Dystrophy pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Myotonic Dystrophy treatment.
• Key Myotonic Dystrophy companies such as Novartis AG, Arrowhead Pharmaceuticals, Inc., Arthex Biotech, Sanofi, DYNE Therapeutics, PepGen Inc., Vertex Pharmaceuticals Incorporated, AMO Pharma, Harmony Biosciences, Ionis Pharmaceuticals, Sarepta Therapeutics, Inc., and Juvena Therapeutics Inc., among others, are involved in developing therapies for the indication.
• Promising Myotonic Dystrophy pipeline therapies in various stages of development include Del-desiran (AOC 1001), ARO-DM1, ATX-01, SAR446268, DYNE-101, PGN-EDODM1, and others.
• The Myotonic Dystrophy pipeline includes Phase III, Phase II, Phase I/II, preclinical, discovery, discontinued, and inactive candidates, reflecting a diverse therapeutic development landscape.

Request a sample and discover the recent advances in Myotonic Dystrophy treatment drugs:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Myotonic Dystrophy?

Myotonic Dystrophy is a chronic, progressive, autosomal dominant disorder characterized by muscle weakness and myotonia, which refers to delayed relaxation of muscles following contraction. There are two major forms: Myotonic Dystrophy type 1 (DM1), also known as Steinert disease, and Myotonic Dystrophy type 2 (DM2), also known as proximal myotonic myopathy. Both are progressive, multisystem genetic disorders.
Myotonic Dystrophy type 1 results from mutations in the DMPK gene, while Myotonic Dystrophy type 2 is caused by mutations in the CNBP gene. In both forms, abnormal expansion of specific DNA repeats produces toxic messenger RNA that disrupts the normal production of multiple proteins, contributing to the multisystem nature of the disease.
The major symptoms include progressive muscle weakness, muscle wasting, and myotonia. The disease can also affect other organs, potentially resulting in cardiac conduction abnormalities, cataracts, infertility, insulin resistance, respiratory complications, and other metabolic disturbances. The severity and progression can vary considerably between individuals.
There is currently no definitive cure for Myotonic Dystrophy. Treatment is primarily focused on managing symptoms and associated complications and may include medications for myotonia, physical therapy, assistive devices, and individualized management of cardiac, respiratory, and metabolic complications.

Emerging Myotonic Dystrophy Drug Profiles

Del-desiran (AOC 1001): Novartis AG
Del-desiran, utilizing Avidity's AOC platform technology, is designed to address the underlying genetic cause of Myotonic Dystrophy type 1 (DM1) by reducing levels of toxic DMPK messenger RNA. Del-desiran consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 (TfR1) and is conjugated to a small interfering RNA (siRNA) targeting DMPK mRNA.
The therapy has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA, as well as Orphan designation from the European Medicines Agency. It was developed by Avidity Biosciences, which has been fully acquired by Novartis AG. Del-desiran is currently being evaluated in Phase III development for Myotonic Dystrophy.

ARO-DM1: Arrowhead Pharmaceuticals, Inc.
ARO-DM1 is an RNA interference (RNAi) conjugate designed to specifically silence DMPK mRNA in skeletal muscle. By reducing aberrantly transcribed DMPK mRNA, the therapy aims to address CUG expansion-related spliceopathies associated with DM1 and potentially improve muscle strength and function.
ARO-DM1 belongs to a class of RNA therapeutics. Preclinical data reported in the DelveInsight report showed greater than 80% silencing of DMPK in skeletal muscle, maintained for more than 85 days. The candidate is currently being evaluated in Phase II development for Myotonic Dystrophy.

ATX-01: Arthex Biotech
ATX-01 is an antimiR oligonucleotide designed to target microRNA-23b (miR-23b), which is involved in the pathogenesis of DM1. The therapy has demonstrated a dual mechanism in human DM1 myoblast cell lines and murine models, reducing toxic DMPK mRNA while increasing MBNL protein production.
ATX-01 was discovered through Arthex's in-house discovery engine, which is designed to identify and optimize novel gene-expression modulators with preferential delivery to disease-relevant tissues. It is currently being evaluated in Phase I/II development for Myotonic Dystrophy.

SAR446268: Sanofi
SAR446268 employs a vectorized RNA interference (RNAi) approach to silence DMPK expression through a single administration. By reducing DMPK transcripts, the therapy aims to eliminate abnormal and toxic RNA foci responsible for splicing defects in muscle tissue, potentially restoring normal splicing and improving muscular function.
The approach is intended to address key manifestations of Myotonic Dystrophy, including progressive muscle weakness and myotonia, as well as effects involving multiple body systems. The U.S. FDA granted Fast Track designation to SAR446268 in September 2025. The candidate is currently being evaluated in Phase I/II development.

Learn more about the novel and emerging Myotonic Dystrophy pipeline therapies:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Myotonic Dystrophy Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Late Stage Products (Phase III), Mid-stage Products (Phase II), Early-stage Products (Phase I), Preclinical and Discovery Stage Candidates, Discontinued & Inactive Candidates
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Key Myotonic Dystrophy Companies: Novartis AG, Arrowhead Pharmaceuticals, Inc., Arthex Biotech, Sanofi, DYNE Therapeutics, PepGen Inc., Vertex Pharmaceuticals Incorporated, AMO Pharma, Harmony Biosciences, Ionis Pharmaceuticals, Sarepta Therapeutics, Inc., Juvena Therapeutics Inc., and others
• Key Myotonic Dystrophy Pipeline Therapies: Del-desiran (AOC 1001), ARO-DM1, ATX-01, SAR446268, DYNE-101, PGN-EDODM1, VX-670, Tideglusib (AMO-02), Pitolisant, IONIS-877864, SRP-1003, JUV-161, and others.

Dive deep into rich insights for new drugs for Myotonic Dystrophy treatment, visit:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Myotonic Dystrophy Pipeline Report Introduction
2. Myotonic Dystrophy Pipeline Report Executive Summary
3. Myotonic Dystrophy Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Myotonic Dystrophy Pipeline Therapeutics
6. Myotonic Dystrophy Pipeline: Late Stage Products (Phase III)
7. Myotonic Dystrophy Pipeline: Mid Stage Products (Phase II)
8. Myotonic Dystrophy Pipeline: Early Stage Products (Phase I)
9. Myotonic Dystrophy Pipeline: Preclinical and Discovery Stage Products
10. Myotonic Dystrophy Pipeline Therapeutics Assessment
11. Inactive Products in the Myotonic Dystrophy Pipeline
12. Myotonic Dystrophy Key Companies
13. Myotonic Dystrophy Key Products in the Pipeline
14. Myotonic Dystrophy - Unmet Needs
15. Myotonic Dystrophy - Market Drivers and Barriers
16. Myotonic Dystrophy - Future Perspectives and Conclusion
17. Myotonic Dystrophy Analyst Views
18. Appendix

For further information on the Myotonic Dystrophy pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

This release was published on openPR.